982P Comparison of donafenib and sorafenib as advanced hepatocellular carcinoma first-line treatments: Subgroup analysis of an open-label, randomized, parallel-controlled, multicentre phase II/III trial.

Authors :: Qin, S.
Bi, F.
Cui, C.
Zhu, B.
Wu, J.
Xin, X.
Wang, J.
Shan, J.
Chen, J.
Zheng, Z.
Xu, L.
Wen, X.
You, Z.
Ren, Z.
Wu, X.
Source :: Annals of Oncology. 2020 Supplement 4, Vol. 31, pS688-S688. 1p.
Publication Year :: 2020

Subjects :: *HEPATOCELLULAR carcinoma
*SUBGROUP analysis (Experimental design)
*SORAFENIB
*THERAPEUTICS

Full Text Access

Tools